Sant P. Chawla, MD, director, Sarcoma Oncology Center, discusses the potential for trabectedin as treatment of mesenchymal chondrosarcoma.
Sant P. Chawla, MD, director, Sarcoma Oncology Center, discusses the potential for trabectedin as treatment of mesenchymal chondrosarcoma.
Mesenchymal chondrosarcoma is a very rare disease that often has a lot of potential to metastasize, Chawla says.
In this small study of fewer than 20 patients, some patients had previously failed standard chemotherapy and trabectedin did control disease in some of those patients for up to two years.
Moving forward, Chawla says, there will first need to be collaboration between institutions and pharmaceutical companies to determine if similar results have been seen before.
Darolutamide Becomes Routine Doublet and Triplet Option in Hormone-Sensitive Prostate Cancer
May 6th 2024Darolutamide has been adopted routinely in clinical practice as a component of both doublet and triplet regimens for the treatment of patients with metastatic hormone-sensitive prostate cancer.
Read More
Responders to UGN-101 Have Positive RFS in Upper Tract Urothelial Cancer
May 5th 2024In patients at 15 centers who had upper tract urothelial cancer, those with no evidence of disease after UGN-101 induction had a 68% rate of 3-year recurrence-free survival, and this outcome did not differ based on tumor status, method of instillation, or treatment intent.
Read More
UGN-101 Shows Promise for Upper Tract Urothelial Cancer Durability
May 5th 2024Maintenance UGN-101 therapy demonstrated good durability of response in initial responders with low-grade upper tract urothelial cancer, as evidenced by a low rate of disease progression in a multicenter, longitudinal follow-up study.
Read More